A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

NCT05915026 | Completed Phase 3 FDA Drug

• 2 other identifiers: 211962022-501883-17-00
• Study Type: interventional
• Target: 93
• Locations: 10 countries
• Sites: 34

Brief Summary

Researchers are looking for a better way to help children under the age of 18 with any known or suspected problems scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI). MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject a contrast agent into a patient's vein to perform a "contrast-enhanced" MRI (CE-MRI). Such CE-MRI examinations may support doctors to identify certain health problems or improve their evaluation. The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd), which is needed for the increase in signal intensity and contrast in MRI. The gadolinium in these contrast agents is caged in a molecule (chelate complex). Researchers are developing new contrast agents with a lower amount of Gd needed per CE-MRI investigation. Gadoquatrane is one of these new contrast agents. It has been tested in several studies previously. The main purpose of this study is to learn how gadoquatrane moves into, through, and out of the body and how safe it is in children. The researchers will measure the amount of gadoquatrane in the blood at different time points after a single injection. The participants will undergo an MRI examination and receive gadoquatrane once at a dose of 0.04 mmol Gd/kg (corresponding to 0.1 mL/kg). It is injected into the participant's vein (also called an intravenous injection) during the MRI examination. Each participant will be in the study for between 8 and 38 days with up to 5 doctor visits, including the screening phase of up to 28 days with no more than 2 visits. Once a participant has received the injection of gadoquatrane, the remaining study duration is 7 (±1) days. At the start or during the study, the doctors and their study team will:

• check the weight and height of the participant,
• ask for information including age and medical history,
• take participants' blood samples,
• ask participants and/or their guardians questions about medicines they are taking,
• check blood pressure, heart rate and body temperature,
• check the area where the participants had the intravenous injection,
• do pregnancy tests in girls of childbearing age,
• review the MRI scans obtained in the study and decide on the diagnosis
• ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

Conditions

Contrast Enhancement in Magnetic Resonance Imaging; Children

Outcome Measures

Primary Outcomes (4)

• Area under the curve (AUC) of gadoquatrane after single administration

  Up to 8 hours post injection

• Plasma clearance normalized to body weight (CL/BW) of gadoquatrane after single administration

  Up to 8 hours post injection

• Apparent volume of distribution at steady state normalized to body weight (Vss/BW) of BAY1747846 after single administration

  Up to 8 hours post injection

• Simulation of plasma concentration at 20 min post-injection (C20)

  At 20 minutes post injection

Secondary Outcomes (4)

• Number of participants with treatment emergent adverse events, including serious adverse events

  Within 24 (± 4) hours post injection

• Number of participants with treatment emergent adverse events, including serious adverse events, per intensity

  Within 24 (± 4) hours post injection

• Number of participants with post-treatment adverse events, including serious adverse events

  Up to 7 (± 1) days after the day of study intervention

• Number of participants with post-treatment adverse events, including serious adverse events, per intensity

  Up to 7 (± 1) days after the day of study intervention

Study Arms (1)

Gadoquatrane

EXPERIMENTAL

Participants will receive one intravenous injection of gadoquatrane during MRI.

Drug: Gadoquatrane (BAY1747846)

Interventions

Gadoquatrane (BAY1747846) DRUG

0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose

Gadoquatrane

Eligibility Criteria

• Age: 0 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Participants from birth to \<18 years of age at the time of signing the informed consent form.
• Participants who have a clinical indication to undergo a CE-MRI for any clinical condition in any body region and who can undergo study procedures as per Investigator judgement.
• Participants can be male or female (according to their reproductive organs and functions assigned by chromosomal complement).
• Female contraception and barriers as well as pregnancy testing is required as appropriate for the age and sexual activity of pediatric participants and as required by local regulations.
• The legal guardian(s) is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• When applicable by law for a participant, a legal guardian must be available to help the study-site personnel ensure follow up, accompany the participant to the study site on each assessment day, and consistently and consecutively be available to provide information on the participant during the scheduled study visits.

You may not qualify if:

• Body weight \<2500 g at screening and baseline
• The medical condition and/or local allowance for maximum blood draw in the pediatric participant is not suitable for study procedures, including pharmacokinetics (PK) and safety blood draws, without compromising any expected clinical care/procedure need.
• Acute kidney injury (i.e., acute renal failure).
• Age-adjusted renal function is "decreased" (eGFR \<80% of age adjusted normal renal function) as evaluated by the investigator based on a serum or plasma creatinine result obtained within 2 weeks prior to study intervention.
• Considered clinically unstable or has a concurrent/concomitant condition that may not allow participation for the full planned study period, in the judgement of the investigator.
• History of moderate to severe allergic-like reaction to any GBCA.
• Bronchial asthma considered unstable or had major therapeutical modification within last 4 weeks.
• Severe cardiovascular disease, except for cardiac or vascular magnetic resonance (MR), if considered clinically justified by the investigator.
• Planned or expected intervention (e.g., treatment or procedure) or change in treatment (e.g. start of chemotherapy) that may significantly affect study parameters (i.e. safety/adverse events \[AEs\] \[e.g. confounding AEs or safety events due to surgery or chemotherapy\], PK parameters) or would prevent the participant from performing study procedures, from the administration of gadoquatrane up to the 24 h ± 4 h follow-up.
• Participants who received or will receive any other contrast agent within 72 hours prior to gadoquatrane injection or up to 72 hours after gadoquatrane injection.
• Contraindications to the administration of GBCAs (depending on local product label), or history of adverse reaction to GBCAs.

Sponsors & Collaborators

• Bayer: lead

Study Sites (34)

Halo Diagnostics - Indian Wells

Indian Wells, California, 92210, United States

Location

Children's Mercy Hospital Kansas City - Radiology

Kansas City, Missouri, 64108, United States

Location

MUSC University Hospital - Radiology

Charleston, South Carolina, 29425, United States

Location

Centro de Diagnostico Enrique Rossi | Departamento de Investigacion Clínica

Ciudad Autonoma de Buenos Aire, Ciudad Auton. de Buenos Aires, C1425BEE, Argentina

Location

Sanatorio Allende | Departamento de Investigación Clínica

Córdoba, X5000JHQ, Argentina

Location

Clinica Universitaria Reina Fabiola | Consultorios Externos

Córdoba, X5004FHP, Argentina

Location

University Multiprofile Hospital for Active Treatment Sveti Georgi | Base II - Radiology Department

Plovdiv, 4000, Bulgaria

Location

Multiprofile Hospital for Active Treatment Central Onco Hospital | Independent Medical Diagnostic Laboratory Mediscan

Plovdiv, 4002, Bulgaria

Location

University Multiprofile Hospital for Active Treatment St. Ivan Rilski | Radiology Department

Sofia, 1431, Bulgaria

Location

University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Radiology Department

Sofia, 1784, Bulgaria

Location

The Hospital for Sick Children (SickKids)

Toronto, Ontario, M5G 1X8, Canada

Location

Beijing Children's Hospital, Capital Medical University

Beijing, Beijing Municipality, 100045, China

Location

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, 510280, China

Location

The Children's Hospital Zhejiang University School of Med

Hangzhou, Hangzhou Province, 310056, China

Location

West China Second University Hospital

Chengdu, Sichuan, 610041, China

Location

Fakultní nemocnice Ostrava

Ostrava - Poruba, 708 52, Czechia

Location

Fakultni nemocnice Plzen - Lochotin

Pilsen, 32300, Czechia

Location

Universitätsklinikum Münster - Klinik für Radiologie, Kinderradiologie

Münster, North Rhine-Westphalia, 48149, Germany

Location

Universitätsklinikum Leipzig - Institut für Kinderradiologie

Leipzig, Saxony, 04103, Germany

Location

Universitätsklinkum Halle (Saale) - Universitätsklinik und Poliklinik für Radiologie, Kinderradiologie

Halle, Saxony-Anhalt, 06120, Germany

Location

Universitätsklinikum Jena - Institut für Diagnostische und Interventionelle Radiologie, Kinderradiologie

Jena, Thuringia, 07747, Germany

Location

Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Pädiatrische Radiologie

Berlin, 13353, Germany

Location

Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital

Nagoya, Aichi-ken, 453-8511, Japan

Location

National Hospital Organization Nagoya Medical Center

Nagoya, Aichi-ken, 460-0001, Japan

Location

Tokai University Hospital

Isehara, Kanagawa, 259-1193, Japan

Location

Kanagawa Children's Medical Center

Yokohama, Kanagawa, 252-8555, Japan

Location

Jichi Medical University Hospital

Shimotsuke, Tochigi, 329-0498, Japan

Location

Juntendo University Hospital

Bunkyo, Tokyo, 113-8431, Japan

Location

Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Children's Medical Center

Fuchū, Tokyo, 183-8561, Japan

Location

National Center for Child Health and Development

Setagaya-ku, Tokyo, 157-8535, Japan

Location

Nara Prefecture General Medical Center

Nara, 630-8581, Japan

Location

Shizuoka Children's Hospital

Shizuoka, 420-8660, Japan

Location

Instytut "Pomnik - Centrum Zdrowia Dziecka"

Warsaw, 04-730, Poland

Location

Karolinska Universitetssjukhuset Solna - Funktion Medicinsk Diagnostik, Barnradiologi

Stockholm, 171 64, Sweden

Location

Related Links

• Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 14, 2023
• First Posted: June 22, 2023
• Study Start: August 16, 2023
• Primary Completion: September 18, 2024
• Study Completion: October 16, 2024
• Last Updated: August 1, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

PL (1); US (3); BU (4); CN (4); AR (3); CA (1); DE (5); SE (1); JP (10); CZ (2)